Anastrozole (arimidex™) in clinical practice versus the old 'gold standard', tamoxifen

Expert Review of Anticancer Therapy

Volumn 2, Issue 6, 2002, Pages 623-629

  Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Advanced breast cancer; Anastrozole; Early breast cancer; Efficacy; Neoadjuvant; Pharmacodynamics; Pharmacokinetics; Safety

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450; ESTROGEN; EXEMESTANE; FADROZOLE; FORMESTANE; GONADORELIN; GONADORELIN ANTAGONIST; GOSERELIN; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT DISORDER; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CORONARY ARTERY THROMBOSIS; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; ENDOMETRIUM CANCER; FEMALE; FIRST PASS EFFECT; HOT FLUSH; HUMAN; HYPERHIDROSIS; LETHARGY; MENOPAUSAL SYNDROME; MUSCULOSKELETAL DISEASE; NAUSEA; OCCLUSIVE CEREBROVASCULAR DISEASE; OVARY FUNCTION; PATHOLOGIC FRACTURE; THROMBOEMBOLISM; TUMOR GROWTH; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VEIN THROMBOSIS; VOMITING; BREAST TUMOR; CHEMISTRY; COMPARATIVE STUDY; DRUG APPROVAL; REVIEW; UNITED STATES;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG APPROVAL; FEMALE; HUMANS; NITRILES; TAMOXIFEN; TRIAZOLES; UNITED STATES;

EID: 0036903041     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.6.623     Document Type: Article

References (28)

1. American Cancer Society Cancer Facts and Figures (2002).
2. Peto R, Boreham J, Clark M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years (letter). Lancet 355, 1822 (2000)
3. Howe HL, Wingo PA,Thun MJ et al. Annual report to the nation on the status of cancer (1973 -1998), featuring cancers with recent increasing trends. J. Natl Cancer Inst. 93 (11), 824-842 (2001).
4. Baum M, Saunders C, Meredith S. Breast Cancer: a guide for every woman. Oxford University Press (1994).
5. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl Cancer Inst. 88(21), 1529-1542 (1996).
6. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol. 13(2), 513-529 (1995).
7. Wells SA, Santen RT, Lipton A et al. Medical adrenalectomy with aminoglutethimide clinical studies in postmenopausal patients with metatastic breast carcinoma. Ann. Surg. 187(5), 475-484 (1978).
8. Goss PE, Powles TJ, Dowsett M et al. Treatment of advanced postmenopausal breast cancer with the aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report. Cancer Res. 46, 4823-4826 (1986).
9. Atac Trialists' Group. Pharmacokinetics of anastrozole and tamoxifen alone and in combination, during adjuvant endocrine therapy in postmenopausal women: a subprotocol of the Arimidex and Tamoxifen Alone or in Combination (ATAC) trial. Br. J. Cancer 85, 317-324 (2001).
10. Dukes M, Edvards PN, Large M, Smith IK, Boyle T. The preclincial pharmacology of 'Arimidex' (anastrozole, ZD 1033) - a potent, selective aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 58, 439-445 (1996).
11. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth generation aromatase inhibitor. Breast Cancer Res. Treat. 30, 103-111 (1994).
12. Esparza-Guerra L, Buzdar A. Anastrozole 'Arimidex does not impair adrenal cortisol or aldosterone synthesis in postmenopausal women with advanced breast cancer. Proc. Ann. Soc. Clin. Oncol. 20, (2001) (Abstract 1954).
13. Muss HB. Endocrine therapy for advanced breast cancer. A review. Br. Cancer Res. Treat. 21, 15-26 (1992).
14. Geisler J, King N, Dowsett M et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma estrogen levels in postmenopausal women with breast cancer. Br. J. Cancer 74(8), 1286-1291 (1996).
15. Geisler J, Anker G, Dowsett M, Lønning PE. Letrozole suppresses plasma estrogen levels in postmenopausal breast cancer patients more completely than anastrozole. Proc. Ann. Soc. Clin. Oncol. 19, 102a, (2000) (Abstract 394).
16. Geisler J, Bernsten L, Ottestad B, Lindtjorn B, Dowsett M, Lønning PE. Neoadjuvant treatment with anastrozole (Arimidex) causes profound suppression of intra-tumor estrogen levels. Proc. Ann. Soc. Clin. Oncol. 18, 82a, (1999) (Abstract 311).
17. Cheung KL, Forward DP, Jackson L, Robertson JFR. Combined use of goserelin (Zoladex) and anastrozole (Arimidex) as second-line endocrine therapy in premenopausal women with advanced breast cancer - a study of its clinical and endocrine effects. Eur. J. Cancer 37 (Suppl. 5), 8, (2001) (Abstract O-22).
18. Yates RA, Dowsett M, Fisher GV et al. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in post-menopausal female volunteers. Br. J. Cancer 73, 543-548 (1996).
19. Camp-Sorrell D. Anastrozole: an effective, second-line hormonal treatment for advanced breast cancer. Cancer Pract. 5, 391-393 (1997).
20. Baldinger SL, Defusco P. Focus of anastrozole: an aromatase inhibitor for the treatment of hormonally dependent advanced breast cancer. Formulary 31, 363-364 (1996).
21. Slaughter RI, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann. Pharmacother. 29, 619-624 (1995).
22. Buzdar AU, Jonat W, Howell A et al. for the Arimidex Study Group: anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature Phase III trials. Cancer 83, 1142-1152 (1998).
23. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women - results of a North American multicenter randomized trial. J. Clin. Oncol. 18(22), 3758-3776 (2000).
24. Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) Study. J. Clin. Oncol. 18 (22), 3748-3757 (2000).
25. Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole ('Arimidex') is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast cancer: results of two randomized trials designed for combined analysis. Cancer 92 (9), 2247-2258 (2001).
26. Dixon JM, Renshaw L, Bellamy C. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin. Cancer Res. 6, 2229-2235 (2000).
27. Milla-Santos A, Milla I, Rallo L, Puig-Gali M. Anastrozole as neoadjuvant therapy for hormone-dependent locally advanced breast cancer in postmenopausal patients. Proc. ASCO 21 (2002) (Abstract 156).
28. Atac Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: fast results of the ATAC randomized trial. Lancet 359, 2131-2139 (2002).